Participant ID:	_	.  _	.  _	_	5	U	U	

DAY FORM Hotline: + 45 4829 6773

Day number: |\_\_|\_| Date |\_\_|\_| - |\_\_||\_| - |\_\_||\_|

#	Question	Answer	Unit	Info	Validation and limits	Further comments for data manager				
Fluids and trial drug										
D1	Cumulated fluid balance on this day	_ _ _ _	mL	All fluid input and output in mL cumulated over 24 hours. This includes all types of IV fluids, blood products, medicines, nutrition products AND oral fluids, nutrition products, and medicine. Daily output as urine, drainage, perspiration, aspirates, stools, bleeding.) The first and last day or in case of referral of the patient to another GODIF ICU the day may be shorter than 24 hours. The fluid balance must be documented with a prefix of + or – in front of the XXXX ml  The first and the last day in this study might have a span for less than 24 hours.	Required	Skal både kunne være et positivt og et negativt tal5000 - +30.000 Præfix nødvendigt Når D1 er < + 1000 ml så skal D7				
D2	Urinary output on this day?	_ _ _ _	mL	24 hours output. Measured at the same time every day. The first and last day or in case of referral of the patient to another GODIF ICU the day may be shorter than 24 hours. If the patient did not have any urinary output on this day type "0".  The first and the last day in this study might have a span for less than 24 hours.	Required					

Day form – 15-06-2020 Page **1** of **12** 

GODIF

## **DAY FORM**

Participant ID:   _ _ _ _		0	G	iC	D	) <b>I</b> F	
---------------------------	--	---	---	----	---	--------------	--

D3	Measured weight in kg on this day	kg	With one decimal	Required	
D4	Cumulative dose of trial drug on this day.	mL	Cumulative dose of trial drug measured at the same time every day. The first and last day or in case of referral of the patient to another GODIF ICU the day may be shorter than 24 hours. An ICU day will often start at 6:00 am or 8:00 am and last 24 hours. This is the same timeframe where the fluid balance is measured. It must be registered according the ICU day definitions at your site.	Required	Hvis der skrives 0 mL, så skal en ny boks åbnes. Hvor der skal stå: why did the patient not receive trial medication? Følgende afkrydsningsbokse: Patient meets pausing criteria, escape RRT, withdrawal from the study, other - describe
D4a	Reason for pausing trial drug:	☐ Neutral fluid balance (-750 to +750 ml) ☐ Escape renal replacement therapy ☐ withdrawal from the study ☐ Other			If other is chosen, go to D4b
D4b	Describe other reason for pausing trial drug				
D5	Plasma concentration of creatinine on this day	Select unit:  µmol/L □  _ _ _   mg/dL □  _ _ _	If several measures of creatinine use highest value.	Required Limits 30- 999 No decimals	Data entry only possible when a unit has been selected (single select only) and only in the field

Day form – 15-06-2020 Page **2** of **12** 

Participant ID:   _ _ _ _	6	G	0	D	IF
---------------------------	---	---	---	---	----

	<u> </u>		T		Τ
		Not available		If value >	corresponding to
				999 μmol/L	selected unit.
				or <30	System will
				μmol/L give	automatically
				warning:	convert between
				"Are you	units (To convert
				sure this is	from mg/dL
				the correct	multiply with 88.4).
				value" – YES	The value of both
				to proceed	units will be visible,
					but only the
					selected unit can
					be corrected. Both
					values will be
					transcribed to
					database.
					WARNING if
					'unobtainable':
					"Are you sure there
					are no measured
					creatinine on this
					day? → "Yes, I'm
					certain" /" No, take
					me back" to
					proceed"
					-
			In case of clinical evidence of significant		Hvis der sættes
			fluid overload or dehydration when the		kryds i YES. Så skal
			cumulative fluid balance is close to neutral		der være to bokse
			according to fluid chart, the clinician can		mere: Dehydration
D6	Indication for a new estimate of	☐YES	revise the estimate for neutral fluid balance.	Doguirod	og clinical fluid
טט	fluid balance?	□NO		Required	overload. Herefter
			In case the clinician sets a new fluid		efterfølgende
			balance. This will be the new target for		bokse under
			fluid removal in this study and MUST be		dehydration:
			documented in the patient file and MUST		weight lower than

Day form – 15-06-2020 Page **3** of **12** 

					. 6					
Participant ID:	ll_	_		ll_	_  (	O	G	U	U	

			be used as a new estimate for cumulative		habitual weight,
			fluid balance		other. (choose one)
					Under clinical fluid
					overload skal der
					være følgende
					valgmuligheder:
					periferal oedema,
					weight higher than
					habitual weight,
					other. (Choose
					one). Der skal til
					sidst komme et felt
					op til det nye
					estimat for
					væskebalancen.
					Hvis YES, så skal
					D6a åbne op
		Reasons for new es	timate of fluid balance		
					Hvis YES skal D6a1
					og D6b åbne op.
D6a	Cignificant clinical fluid avarland	☐YES		Required if	Hvis NO i
Dog	Significant clinical fluid overload	□NO		D6 is YES	D6a1+D6b skal D6c
					åbne op.
D6a1	Peripheral oedemas	☐YES		Required if	
Doar	Periprieral dedernas	NO		D6a is YES	
D6b	Weight higher than habitual	☐YES		Required if	
מסט	weight	□NO		D6 is YES	
	Explain with the patient is				
D6c	significant overhydrated which is				
DOC	not due to oedemas or weight				
	gain.				

Day form – 15-06-2020 Page **4** of **12** 

**GODIF** 

## **DAY FORM**



D6d	Dehydration	☐ YES ☐ NO		Required if D6 is NO	Hvis YES så skal D6d1 og 2 åbne op.
D6d1	Weight lower than habitual weight	☐ YES ☐ NO		Required if D6b is YES	Ved NO i D6b1+2 skal D6d3 åbnes
D6d2	Clinical signs of dehydration with low blood pressure and reduced skin turgor.	□ YES □ NO		Required if D6b is YES	Ved NO i D6d1+2 skal D6d3 åbnes
D6d3	Explain why the patient is dehydrated which is not due to weight loss or clinical signs of dehydration			Required if NO i D6d1 og 2	
D6e	New estimate of fluid balance	ml	Must be documented with a prefix of + or – in front of the new estimate.	Required if D6 is YES	Her skal der kunne skrives et tal der både er positivt og negativt, hvorfor præfix med +/- er nødvendig5000 til + 20.000 ml (ref. ramme)
		Major protocol v	iolations on this day		
D7	Discontinuation of goal directed fluid removal for 2 days before a neutral cumulative fluid balance has been achieved?	□ YES □ NO	Trial drug paused or not titrated to effect according to protocol/algorithm	Required	
D8	Continuation of administration of trial drug for 2 days despite fulfilling pausing criteria resulting in a negative cumulative fluid balance (< - 750 ml)?	□ YES □ NO	This does not include maintenance dose of trial drug to maintain a neutral fluid balance	Required	
D9	Is extra furosemide administered without the presence of escape indications?	□ YES □ NO	Furosemide not dosed as escape medicine or as habitual furosemide. Escape indication for open-label furosemide are: Hyperkalaemia (p-K > 6 mmol/l), respiratory failure (P/F-ratio < 26 kPa (200 mmHg)) and	Required	

Day form – 15-06-2020 Page **5** of **12** 

Participant ID:   _ _ _	
-------------------------	--

			pulmonary oedema if treating physician has a suspicion of respiratory deterioration is due to fluid overload. Reason for escape doses must be described in the medical record. The maximum dose of furosemide per 24 hours is 1500 mg and must not be exceeded.		
D10	Administration of other diuretics outside this protocol?	☐ YES ☐ NO	Other diuretics the patient is not normally treated with before admittance to the hospital. This does not include thiazides administered to treat hypernatraemia.	Required	
D11	Initiation of renal replacement therapy (RRT) without the presence of RRT escape indications?	☐ YES ☐ NO	The escape indications for RRT: Hyperkalaemia (p-K > 6 mmol/l) OR respiratory failure (P/F-ratio < 26 kPa (200 mmHg)) and pulmonary oedema if treating physician has a suspicion of respiratory deterioration is due to fluid overload OR severe metabolic acidosis attributable to AKI (pH < 7.20 and SBE < -10 mmol/L) OR persistent AKI > 72 h (defined as: oliguria/anuria or s-creatinine has not declined to 50% from peak value).	Required	
D12	Participants withdrawing or withdrawn from the allocated intervention despite having fluid overload. This includes patients discontinued from the trial by the choice of the patient or the clinician for other reasons than SAR/SAEs or SUSARs.	☐ YES ☐ NO			
		Co-inte	erventions		

Day form – 15-06-2020 Page **6** of **12** 

Participant ID:	1 1	1 1	1 1	1 1 6	G		
i ai dicipant ib.		I —— I ——	I — I —	II	U	U	

D13	Did the patient receive infusion of vasopressors or inotropes on this day?	□ YES □ NO	Vasopressor/inotrope agents: norepinephrine, epinephrine, phenylephrine, vasopressin analogues, angiotensin, dopamine, dobutamine, milrinone or levosimendan.	Required	
D14	Did the patient receive mechanical ventilation on this day?	☐ YES ☐ NO	Invasive or non-invasive mechanical ventilation as the use of positive pressure ventilation using a ventilator. CPAP alone is NOT mechanical ventilation	Required	
D15	Use of escape renal replacement therapy on this day?	☐ YES ☐ NO	Any form of renal replacement therapy (e.g. dialysis, hemofiltration or hemodiafiltration) at any rate on this day.	Required	Hvis YES, så skal nedenstående 4 felter åbnes op.
D15a	Was the reason hyperkalaemia (p-K > 6 mmol/l)?	□YES □NO		Required if D15 is YES	
D15b	Was the reason respiratory failure (P/F-ratio < 26 kPa (200 mmHg)) and pulmonary oedema due to fluid overload?	□YES □NO		Required if D15 is YES	
D15c	Was the reason severe metabolic acidosis attributable to AKI (pH < 7.20 and SBE < -10 mmol/L)	☐ YES ☐ NO		Required if D15 is YES	
D15d	Was the reason persistent AKI > 72 h (defined as: oliguria/anuria or s-creatinine has not declined to 50% from peak value)?	□ YES □ NO		Required if D15 is YES	
D16	Use of escape open-label furosemide on this day?	☐ YES ☐ NO	open label furosemide can only be used in case of: Hyperkalaemia (p-K > 6 mmol/l) or	Required	Ved YES – da skal der komme et felt

Day form – 15-06-2020 Page **7** of **12** 

Participant ID:	<u> </u>			 <u> </u>	 <u> </u>	0	G	0	D	IF	
										_	

			respiratory failure (P/F-ratio < 26 kPa (200 mmHg)) and pulmonary oedema if treating physician has a suspicion of respiratory deterioration is due to fluid overload Escape doses must be described in the medical record. The maximum dose of furosemide per 24 hours is 1500 mg and must not be exceeded.		op med total dose of open-label furosemide mg				
D16a	Total dose of open-label furosemide on this day?	mg		Required if YES in D15					
D16	Use of resuscitation algorithm on this day?	□ YES □ NO	Situation with severe hypoperfusion or severe circulatory impairment: lactate ≥ 4 mmol/l, MAP < 50 mmHg (+/-vasopressor/inotrope), mottling beyond edge of kneecap (mottling score > 2).	Required					
	Serious adverse events  If the patient experiences a SAE the coordinating center must be informed by email within 24 hours.  Mail: godif@cric.dk or by telephone +45 4829 6773								
SAE1	Did the patient have cerebral ischemia on this day?	□YES □NO	Defined as any form of cerebral ischemia on a CT- OR MRI scan on this day?	Required					

Day form – 15-06-2020 Page **8** of **12** 

Participant ID:   _ _ _ _	<b>@GODIF</b>
---------------------------	---------------

SAE3	Did the nationt have limb	☐ YES ☐ NO	Defined as ischemia verified by endoscopy OR open surgery on this day?  Defined as clinical signs AND need of open/percutaneous vascular intervention,	Required  Required	
SAE2	Did the patient have acute myocardial ischemia on this day?	□ YES □ NO	Defined as participant with acute myocardial infarction (ST-elevation myocardial infarction or non-ST elevation myocardial infarction) or unstable angina pectoris according to the criteria in the clinical setting in question (e.g. elevated biomarkers, ischemic signs on ECG and clinical presentation) AND the participant received treatment as a consequence of this (reperfusion strategies (PCI/thrombolysis) OR initiation/increased antithrombotic treatment).	Required	

Day form – 15-06-2020 Page **9** of **12** 



SAE5	Did the patient develop a new episode for acute kidney injury stage 3 on this day? (see link for definition)	☐ YES ☐ NO	AKI modified KDIGO stage 3: A 3 times increase in baseline p-creatinine or increase in p-creatinine to ≥ 354 µmol/L or use of renal replacement therapy (any form) because of renal failure.	Required	Dette felt skal være utilgængeligt på dayform 1 eller forklaring i infobox om at AKI grad 3 ikke er en SAE når man kommer ind I studiet med tilstanden
SAE6	Did the patient experience atrial fibrillation for the first time?	☐ YES ☐ NO	New onset atrial fibrillation. The patient has never had atrial fibrillation before.	Required	Hvis der svares YES til dette felt, så skal det efterfølgende blive inaktivt, da man ikke kan have new onset atrial fibrillation mere end en gang.
		Serious Adv	verse Reactions		
	If the pat	ient experiences a SAR, the	e coordinating center must be contacted	d	
	by e	e-mail godif@cric.nu or pho	one +45 4829 6773 within 24 hours.		
SAR1	Anaphylactic reaction on this day?	☐ YES ☐ NO	Urticaria and at least one of the following:  - Worsened circulation (> 20% decrease in blood pressure or > 20% increase in vasopressor dose)  - Increased airway resistance (>20% increase in the peak pressure on the ventilation)  - Clinical stridor or bronchospasm  - Subsequent treatment with bronchodilators	Required	WARNING if YES Remember to contact the coordinating centre without undue delay at godif@cric.nu or +45 4829 6773

Day form – 15-06-2020 Page **10** of **12** 

SAR2	General tonic-clonic seizures on this day?	☐ YES ☐ NO	Stiffening and/or jerking movements of all 4 extremities in a patient who becomes or is unconscious in the ICU after randomisation	Required	WARNING if YES Remember to contact the coordinating centre without undue delay at godif@cric.nu or +45 4829 6773
SAR3	Severe electrolyte disturbance of p-K < 2.5 mmol/L, p-Na < 120 mmol/L, p-Cl < 90 mmol/L on this day?	☐ YES ☐ NO	On any plasma sample, including point-of- care testing, done in the ICU after randomisation and start of trial drug.	Required	WARNING if YES Remember to contact the coordinating centre without undue delay at godif@cric.nu r+45 4829 6773
SAR4	Agranulocytosis on this day?	☐ YES ☐ NO	Agranulocytosis is defined as any new drop in granulocytes to < 0.5 x 10 <sup>9</sup> /L	Required	WARNING if YES Remember to contact the coordinating centre without undue delay at godif@cric.nu r+45 4829 6773
SAR5	Aplastic anaemia on this day?	☐ YES ☐ NO	defined as a syndrome of bone marrow failure characterized by peripheral pancytopenia and morrow hypoplasia. Drop in haemoglobin < 5.0 mmol/L, neutrophil leucocytes < 0.5 x 10 <sup>9</sup> /L, thrombocytes < 20 x 10 <sup>9</sup> /L, reticulocytes < 1 %.	Required	WARNING if YES Remember to contact the coordinating centre without undue delay at godif@cric.nu r+45 4829 6773
SAR6	Pancreatitis on this day?	□YES □NO	Diagnosed after randomisation and start of trial drug.	Required	WARNING if YES Remember to contact the coordinating centre without undue delay at godif@cric.nu or +45 4829 6773

Day form – 15-06-2020 Page **11** of **12** 

Participant ID:	lI.		<u>  </u> _	_ _		G	U	U	

SAR7	Circulatory collapse leading to cardiac arrest on this day?	□YES □NO		Required	WARNING if YES Remember to contact the coordinating centre without undue delay at godif@cric.nu r+45 4829 6773
SAR8	Steven Johnsons syndrome on this day?	□ YES □ NO		Required	WARNING if YES Remember to contact the coordinating centre without undue delay at godif@cric.nu or +45 4829 6773
SAR9	Toxic epidermal necrolysis on this day?	□YES □NO		Required	WARNING if YES Remember to contact the coordinating centre without undue delay at godif@cric.nu or +45 4829 6773
SAR10	Hearing impairment/loss on this day?	□ YES □ NO	The patient complaining of hearing impairment (not former known).	Required	WARNING if YES Remember to contact the coordinating centre without undue delay at godif@cric.nu or +45 4829 6773

Day form – 15-06-2020 Page **12** of **12**